Magellan Biologicals

Magellan Biologicals is an Australian biotechnology company specializing in the discovery and development of novel peptide therapeutics derived from animal venoms. Utilizing a proprietary venomics platform, the company identifies bioactive peptides with high potency and selectivity for validated therapeutic targets, particularly ion channels. Their research primarily focuses on addressing unmet needs in chronic pain, inflammatory conditions, and metabolic diseases. Magellan leverages the natural evolutionary optimization of venom peptides to create stable, drug-like leads for clinical development. The company's lead programs target voltage-gated sodium channels for the treatment of chronic and neuropathic pain.